Elutia secures $15 million loan financing from Avenue Capital Group
ELUT•Elutia signs $15 million growth capital loan facility
Elutia signed a $15 million growth capital loan facility with Avenue Capital to fund development and commercialization of NXT-41x.
$10 million was funded at closing; the remaining $5 million tranche unlocks upon FDA 510(k) clearance for NXT-41x.
Proceeds target first-half 2027 FDA clearance timeline
Proceeds target an anticipated first-half 2027 FDA clearance timeline, supporting a planned launch into a $1.5 billion U.S. market.
